Top

Published in:

01-06-2014 | Original Article

Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma

Authors: Shogo Kumagai, Masaharu Tashima, Jun Fujikawa, Makoto Iwasaki, Yoshihiro Iwamoto, Yuki Sueki, Akiko Fukunaga, Soshi Yanagita, Momoko Nishikori, Akifumi Takaori-Kondo, Nobuyoshi Arima

Published in: International Journal of Hematology | Issue 6/2014

Abstract

The prognosis of follicular lymphoma (FL) is significantly associated with host immunity and tumor microenvironment. Lymphopenia has been identified as a negative prognostic factor for FL. The association between monocytosis and progression-free survival (PFS) in FL remains controversial. It is unknown whether the ratio of peripheral blood absolute lymphocyte count to absolute monocyte count (ALC/AMC) at diagnosis is associated with FL prognosis. We studied 99 consecutive patients with FL who were treated with rituximab-containing chemotherapy at Kitano Hospital or Kyoto University Hospital between 2000 and 2012. We analyzed individual variables associated with the ALC/AMC ratio before treatment, as well as known prognostic factors of FL, and found that an ALC/AMC ratio of 4.7 was the best cut-off value for PFS. Kaplan–Meier analysis showed that a decreased ALC/AMC ratio was associated with inferior PFS (P = 0.022). Multivariate analysis showed that a decreased ALC/AMC ratio was a significant poor prognostic factor independent of other variables (hazard ratio, 2.714; 95 % confidence interval, 1.060–6.948; P = 0.037). The ALC/AMC ratio before treatment may be a significant prognostic factor predicting PFS of FL.

Available only for authorised users

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification project. Blood 1997; 89:3909-18.

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.PubMedCrossRef

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2. J Clin Oncol. 2009;27:4555–62.PubMedCrossRef

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.PubMedCrossRef

Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97:262–9.PubMedCentralPubMedCrossRef

Koh YW, Kang HJ, Park C, Yoon DH, Kim S, Suh C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist. 2012;17:871–80.PubMedCentralPubMedCrossRef

Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012;157:321–30.PubMedCrossRef

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.PubMedCrossRef

Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef

10.

Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51:199–212.PubMedCrossRef

11.

Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92(2):246–54.PubMedCrossRef

12.

Parker D, Alison DL, Barnard DL, Child JA, Dovey G, Farish J, et al. Prognosis in low grade non-Hodgkin’s lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematol Oncol. 1994;12:15–27.PubMedCrossRef

13.

Decaudin D, Des Guetz G, Mathiot C, Dumont J, Hubert P, Vincent-Salomon A, et al. Absolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy. Ann Oncol. 2003;14:171–2.PubMedCrossRef

14.

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.PubMedCentralPubMedCrossRef

15.

Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.PubMedCrossRef

16.

Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res. 2013;37:1213–5.PubMedCrossRef

17.

Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, et al. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012;53:575–80.PubMedCrossRef

18.

Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14 + HLA-DR (low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117:872–81.PubMedCentralPubMedCrossRef

19.

Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, et al. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res. 2013;37:1208–12.PubMedCrossRef

Title: Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma
Authors: Shogo Kumagai
Masaharu Tashima
Jun Fujikawa
Makoto Iwasaki
Yoshihiro Iwamoto
Yuki Sueki
Akiko Fukunaga
Soshi Yanagita
Momoko Nishikori
Akifumi Takaori-Kondo
Nobuyoshi Arima
Publication date: 01-06-2014
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 6/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1576-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Primary B-lymphoblastic lymphoma of gallbladder involving mandibular bone

SCF/C-KIT signaling modulates tryptase expression in acute myeloid leukemia cells

Regulation of hematopoiesis in endosteal microenvironments

Transient abnormal myelopoiesis in a phenotypically normal newborn with polyclonal trisomy 21

Influences of vascular niches on hematopoietic stem cell fate

Guest editorial: hematopoietic regulators in the marrow: new players in inter-organ communication

Keynote webinar | Spotlight on antibody–drug conjugates in cancer